Roche Holding AG is talking about spinning off its vitamin and fine chemicals division. The company is currently considering strategic options with this division and much of the market expects an outright sale.
The division's strength lies in its large product range, suggesting that splitting the division into components wasn't likely.
Roche is facing heavy costs of fines and lawsuits over the division's price fixing and selling the vitamins division would also allow the organization to focus on its drug business, whose performance has lagged behind the markets.
Roche apparently has no plans to amend its share structure for the foreseeable future.
Roche shares fell 28 percent last year, despite pharmaceutical sales growth of six percent. Industry average growth was 8 percent.
Investor confidence will be largely dependent on Roche's growth in the pharma business.